Key Takeaways:
- Arcutis Biotherapeutics (ARQT, Financial) nearly doubled its Q1 2025 revenues to $63.8 million.
- Strong ZORYVE prescription demand rose by 10% despite seasonal challenges.
- Analysts forecast significant growth potential with a target price upside of 46.65%.
Arcutis Biotherapeutics Inc. (ARQT) reported impressive growth in its financial performance for the first quarter of 2025. The company nearly doubled its revenues, reaching $63.8 million. This substantial increase was predominantly driven by a 10% rise in demand for its key product, ZORYVE, even in the face of seasonal challenges. With a robust financial position of $198.7 million in cash and securities, Arcutis is poised for continued expansion, especially with anticipated upcoming product approvals.
Wall Street Analysts Forecast
According to projections by seven analysts, Arcutis Biotherapeutics Inc (ARQT, Financial) is expected to reach an average price target of $21.00 over the next year. This estimate includes a high of $29.00 and a low of $19.00, suggesting a noteworthy potential upside of 46.65% from its current trading price of $14.32. For more comprehensive data, visit the Arcutis Biotherapeutics Inc (ARQT) Forecast page.
The brokerage consensus presents an optimistic outlook for ARQT, carrying an average recommendation score of 1.7, which corresponds to an "Outperform" status. The rating system ranges from 1 to 5, where 1 indicates a Strong Buy, and 5 suggests a Sell.
